Observational studyAnnals of the rheumatic diseases2022

Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study.

Laure Gossec et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.